Two investigations by the UK’s Competition and Markets Authority over behaviour around prochlorperazine and nitrofurantoin have been put on hold due to the coronavirus pandemic.

With a clear plan to move on niche and differentiated generics, complex specialty and value-added medicines, Advanz Pharma has agreed to buy debt-ridden Correvio Pharma and the rights to a portfolio from UCB, at the same time as shareholders opted to move to delist the company’s shares.

In a move expected to unlock operational and cost efficiencies, Advanz Pharma is moving its legal and tax domicile to Jersey, close to its strategic focus on western European markets.